Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Alnylam Pharmaceuticals (ALNY)

Alnylam Board: Bonney and Bertozzi Resign; Stuart Arbuckle Named Director

Neutral Impact 2 of 5 leadership Written later

Two Alnylam directors, Michael W. Bonney and Carolyn Bertozzi, resigned from the board effective December 2, 2025, and the board cut its size from eleven to ten seats. The board also elected Stuart A. Arbuckle as a non-employee director, effective January 5, 2026, with a $75,000 annual cash retainer and a $600,000 stock option grant. The filing states that the resignations did not stem from any disagreement with the company on its operations, policies or practices.

Key points

  • Michael W. Bonney and Carolyn Bertozzi resigned from the board effective December 2, 2025; the filing states no disagreement with the company caused either resignation
  • Board size reduced from eleven to ten directors
  • Stuart A. Arbuckle elected as a Class I director effective January 5, 2026, with a $75,000 annual cash retainer and a stock option grant with a $600,000 grant date fair value
  • Dr. Bertozzi is joining the board of Eli Lilly effective December 8, 2025, and will continue as a scientific advisor to Alnylam

The filing

CompanyAlnylam Pharmaceuticals (ALNY)
Form8-K, current report
Filed with the SECDec 3, 2025, 4:49 PM ET
Accession number0001628280-25-055084

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.